Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).
Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).
Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy, and brain metastases (Abstract YR4).
Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).
